329 related articles for article (PubMed ID: 25187203)
1. Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials.
Vanassche T; Hirsh J; Eikelboom JW; Ginsberg JS
Thromb Haemost; 2014 Nov; 112(5):918-23. PubMed ID: 25187203
[TBL] [Abstract][Full Text] [Related]
2. Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants.
Weitz JI; Pollack CV
Thromb Haemost; 2015 Nov; 114(6):1113-26. PubMed ID: 26155974
[TBL] [Abstract][Full Text] [Related]
3. [Effective, safe stroke prevention with novel oral anticoagulants in patients with atrial fibrillation. Focus on dabigatran].
Szapary L; Fehér G; Bosnyák E; Deli G; Csécsei P
Ideggyogy Sz; 2013 May; 66(5-6):165-74. PubMed ID: 23909016
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
Senoo K; Lip GY
Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
[TBL] [Abstract][Full Text] [Related]
5. Novel anticoagulants for stroke prevention in patients with atrial fibrillation.
Jalota A; Scarabelli TM; Saravolatz L; Bakhsh MU; Agrawal P; Jalota R; Chen-Scarabelli C; Fuster V; Halperin J
Cardiovasc Drugs Ther; 2014 Jun; 28(3):247-62. PubMed ID: 24842559
[TBL] [Abstract][Full Text] [Related]
6. [The X-VeRT study].
Colonna P; Troccoli R; Botto GL
G Ital Cardiol (Rome); 2015 Jun; 16(6):325-8; discussion 328-30. PubMed ID: 26156692
[No Abstract] [Full Text] [Related]
7. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
[TBL] [Abstract][Full Text] [Related]
8. [Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation].
Saliba L; Mondoly P; Duparc A; Bura-Rivière A; Maury P; Calmels V; Sallerin B; Pathak A; Montastruc JL; Bagheri H
Therapie; 2015; 70(6):485-92. PubMed ID: 26223162
[TBL] [Abstract][Full Text] [Related]
9. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
Mantha S; Ansell J
Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
[TBL] [Abstract][Full Text] [Related]
10. Differential cellular effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis.
Schurgers LJ; Spronk HM
Thromb Haemost; 2014 Nov; 112(5):909-17. PubMed ID: 25298033
[TBL] [Abstract][Full Text] [Related]
11. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
12. Intracranial bleedings in patients on long-term anticoagulant treatment: Benefits from oral thrombin and factor Xa inhibitors in clinical practice.
Łukasik M; Zawilska K; Undas A
Neurol Neurochir Pol; 2015; 49(3):171-9. PubMed ID: 26048605
[TBL] [Abstract][Full Text] [Related]
13. Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials.
Kwong JS; Lam YY; Yan BP; Yu CM
Cardiovasc Drugs Ther; 2013 Feb; 27(1):23-35. PubMed ID: 23224686
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence.
Martínez-Rubio A; Dan GA; Kaski JC
Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):933-47. PubMed ID: 24948333
[TBL] [Abstract][Full Text] [Related]
15. Why switch from warfarin to NOACs?
Verdecchia P; Angeli F; Aita A; Bartolini C; Reboldi G
Intern Emerg Med; 2016 Apr; 11(3):289-93. PubMed ID: 26972708
[TBL] [Abstract][Full Text] [Related]
16. Novel oral anticoagulants in non-valvular atrial fibrillation.
Potpara TS; Lip GY
Best Pract Res Clin Haematol; 2013 Jun; 26(2):115-29. PubMed ID: 23953900
[TBL] [Abstract][Full Text] [Related]
17. New oral anticoagulants in elderly patients.
Barco S; Cheung YW; Eikelboom JW; Coppens M
Best Pract Res Clin Haematol; 2013 Jun; 26(2):215-24. PubMed ID: 23953909
[TBL] [Abstract][Full Text] [Related]
18. Novel oral anticoagulants in secondary prevention of stroke.
Diener HC; Easton JD; Hankey GJ; Hart RG
Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Nonvitamin K Oral Anticoagulants in Patients with Atrial Fibrillation and Cancer: A Study-Level Meta-Analysis.
Cavallari I; Verolino G; Romano S; Patti G
Thromb Haemost; 2020 Feb; 120(2):314-321. PubMed ID: 31785599
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W
Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
